文献速递心力衰竭与心肌病

达格列净对DAPA-HF试验中基线收缩压的影响

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
PubMed 文献 · Eur Heart J · 2020-01-01

DAPA-HF试验事后分析评估达格列净在HFrEF患者中按基线收缩压分层的疗效与安全性。各SBP组中达格列净的获益与安全性一致,主要复合终点风险比无显著交互作用,且各SBP组停药率无差异。

要点

  • 达格列净在各基线SBP组中均优于安慰剂,主要结局HR一致。
  • 基线SBP最低组主要结局发生率最高,但达格列净仍安全有效。
  • 各SBP组中达格列净与安慰剂的停药率无差异。

核心结论

  • 在HFrEF患者中,达格列净对SBP影响较小,且在DAPA-HF纳入的SBP范围内均优于安慰剂改善结局且耐受良好。

研究设计与样本

  • DAPA-HF试验的事后分析,纳入NYHA II-IV级、LVEF≤40%、NT-proBNP升高且SBP≥95 mmHg的患者。
  • 主要结局为心力衰竭恶化或心血管死亡的复合终点。

主要发现

  • 达格列净较安慰剂从基线至2周校正的SBP降幅为-2.54(-3.33至-1.76)mmHg(P<0.001)。
  • 最低SBP组主要结局发生率(每100人年)为20.6(95%CI 17.6-24.2),最高SBP组为13.8(95%CI 11.7-16.4)。
  • 各SBP组(从最低到最高)主要结局风险比(95%CI)分别为0.76(0.60-0.97)、0.76(0.57-1.02)、0.81(0.61-1.08)、0.67(0.51-0.87),P交互=0.78。
  • 各SBP组中达格列净与安慰剂的停药率无差异。

关键数值与推荐

  • 关键入选标准:NYHA II-IV级、LVEF≤40%、NT-proBNP升高、SBP≥95 mmHg。

临床怎么用

  • 对于HFrEF患者,即使基线SBP较低(≥95 mmHg),达格列净仍可考虑使用且耐受良好。

局限性

  • 本研究为DAPA-HF试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). METHODS AND RESULTS: Key inclusion criteria were: New York Heart Association Class II-IV, left ventricular ejection fraction ≤ 40%, elevated N-terminal pro-B-type natriuretic peptide level, and SBP ≥95 mmHg. The primary outcome was a composite of worsening heart failure or cardiovascular death. The efficacy and safety of dapagliflozin were examined using SBP as both a categorical and continuous variable. A total of 1205 patients had a baseline SBP <110 mmHg; 981 ≥ 110 < 120; 1149 ≥ 120 < 130; and 1409 ≥ 130 mmHg. The placebo-corrected reduction in SBP from baseline to 2 weeks with dapagliflozin was -2.54 (-3.33 to -1.76) mmHg (P < 0.001), with a smaller between-treatment difference in patients in the lowest compared to highest SBP category. Patients in the lowest SBP category had a much higher rate (per 100 person-years) of the primary outcome [20.6, 95% confidence interval (95% CI) 17.6-24.2] than those in the highest SBP category (13.8, 11.7-16.4). The benefit and safety of dapagliflozin was consistent across the range of SBP; hazard ratio (95% CI) in each SBP group, lowest to highest: 0.76 (0.60-0.97), 0.76 (0.57-1.02), 0.81 (0.61-1.08), and 0.67 (0.51-0.87), P interaction = 0.78. Study drug discontinuation did not differ between dapagliflozin and placebo across the SBP categories examined. CONCLUSION: Dapagliflozin had a small effect on SBP in patients with HFrEF and was superior to placebo in improving outcomes, and well tolerated, across the range of SBP included in DAPA-HF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03036124.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Serenelli M, Böhm M, Inzucchi SE, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020. PMID: 32820334. doi:10.1093/eurheartj/ehaa496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。